Program
Metronidazole
Also written as “metronidazole 1% gel”, “Metronidazole Tablet” and “metronidazole”.
Its studies are mostly in Intraabdominal Infections · Vaginosis, Bacterial · Rosacea · Appendicitis · Skin Manifestations, led by 11 companies.
Drug pageMetronidazole: every studyMany companies study it; this page follows only the 27 they lead. All 226 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 80 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Galderma Groupits history only | 40 open or running | phase 4since Feb 16, 2007 | Feb 16, 2007 | none ahead |
| S.L.A. Pharmaits history only | 40 open or running | phase 3since Jul 30, 2007 | Jul 30, 2007 | none ahead |
| Curatek Pharmaceuticalsits history only | 20 open or running | phase 3since Dec 1, 2014 | Dec 1, 2014 | none ahead |
| Par Healthits history only | 20 open or running | phase 1since Jun 16, 2011 | Jun 16, 2011 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 2since Nov 24, 2009 | Nov 24, 2009 | none ahead |
| Appili Therapeuticsits history only | 10 open or running | phase 1since Nov 6, 2017 | Nov 6, 2017 | none ahead |
| bioRASIits history only | 10 open or running | phase 3since Mar 12, 2015 | Mar 12, 2015 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 2since Mar 19, 2012 | Mar 19, 2012 | none ahead |
| Insud Pharmaits history only | 10 open or running | phase 4since Mar 4, 2015 | Mar 4, 2015 | none ahead |
| Saptalis Pharmaceuticals | 11 open or running | phase 2since Aug 8, 2025 | Aug 8, 2025 | none ahead |
Also a collaborator on its studies: Allergan Sales, AbbVie, Algorithme Pharma and PriCara, Unit of Ortho-McNeil.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Saptalis Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 8, 2025First study: phase 2 study in Bacterial InfectionsFirst studyNCT07146217 · 30 planned · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“DNA inhibitor; DNA inhibitor”ChEMBL 37, by rule
Studies
The one study Saptalis Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07146217Bacterial Infections · United States | 2 | Not yet recruiting | Jul 2026 | 30 |
How it is read
Names in the registry
- “Metronidazole”, 20 entries
- “metronidazole 1% gel”, 2 entries
- “Metronidazole Tablet”, 2 entries
- “metronidazole”, 2 entries
- “Likmez® (metronidazole) Oral Suspension”, 1 entry
Conditions, from the studies’ own filings
- Intraabdominal Infections, 7 studies
- Vaginosis, Bacterial, 4 studies
- Rosacea, 3 studies
- Appendicitis, 3 studies
- Skin Manifestations, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.